JW Lifescience Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
JW Lifescience has a total shareholder equity of ₩163.4B and total debt of ₩46.2B, which brings its debt-to-equity ratio to 28.3%. Its total assets and total liabilities are ₩260.4B and ₩96.9B respectively. JW Lifescience's EBIT is ₩31.2B making its interest coverage ratio 28.3. It has cash and short-term investments of ₩34.5B.
Anahtar bilgiler
28.3%
Borç/özkaynak oranı
₩46.18b
Borç
| Faiz karşılama oranı | 28.3x |
| Nakit | ₩34.53b |
| Eşitlik | ₩163.44b |
| Toplam yükümlülükler | ₩96.95b |
| Toplam varlıklar | ₩260.39b |
Son finansal sağlık güncellemeleri
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12
Recent updates
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year
Mar 11What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?
Feb 21Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?
Feb 02We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?
Dec 23Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 23How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?
Nov 27Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: A234080's short term assets (₩120.3B) exceed its short term liabilities (₩64.5B).
Uzun Vadeli Yükümlülükler: A234080's short term assets (₩120.3B) exceed its long term liabilities (₩32.4B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: A234080's net debt to equity ratio (7.1%) is considered satisfactory.
Borcun Azaltılması: A234080's debt to equity ratio has reduced from 43.3% to 28.3% over the past 5 years.
Borç Kapsamı: A234080's debt is well covered by operating cash flow (54%).
Faiz Kapsamı: A234080's interest payments on its debt are well covered by EBIT (28.3x coverage).